Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1998 March;42(1) > The Quarterly Journal of Nuclear Medicine 1998 March;42(1):33-42

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

ORIGINAL ARTICLES  BREAST CANCER II 

The Quarterly Journal of Nuclear Medicine 1998 March;42(1):33-42

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Radioimmunolocalization of primary and metastatic breast cancer

Baum R. P., Brummendorf T. H.*

From the Department of Nuclear Medicine University Medical Center Frankfurt/Main, Germany and the *Department of Hematology Oncology and Immunology University Medical Center, Tübingen, Germany


PDF


The appro­pri­ate ther­a­py for ­breast can­cer ­depends main­ly ­upon ear­ly and reli­able ­tumor detec­tion, cor­rect ­tumor stag­ing and accu­rate re-stag­ing ­after ther­a­py. Current radio­log­i­cal imag­ing meth­ods are ­based pri­mar­i­ly on mor­phol­o­gy result­ing in ­high sen­si­tiv­ity but lack­ing spec­i­fic­ity. Established nucle­ar med­i­cine tech­niques are sen­si­tive but not ­very spe­cif­ic. To ­improve spec­i­fic­ity, a num­ber of mono­clo­nal anti­bod­ies, select­ed ­against a par­tic­u­lar ­tumor-asso­ciat­ed anti­gen ­expressed on the sur­face of ­breast can­cer ­cells, ­have ­been radio­lab­eled for imag­ing in ­vivo ­tumor local­iza­tions. In the­o­ry, radio­im­mu­nod­e­tec­tion ­offers the poten­tial to dem­on­strate can­cer ­cells ­even in sub­ra­dio­log­i­cal dis­ease, or ­when anat­o­my-­based imag­ing meth­ods may be ­unable to dis­tin­guish the ­nature of an evi­dent ­mass, mak­ing the dif­fe­ren­tial diag­no­sis ­between an inflam­ma­to­ry reac­tion, a ­postsur­gi­cal fibro­sis, or a tru­ly ­viable ­tumor impos­sible. Suspected ­tumor recur­rence indi­cat­ed by increas­ing ­tumor mark­er lev­els ­could be ­another clin­i­cal indi­ca­tion for radio­im­mu­nol­o­cal­iza­tion, ­even if stan­dard imag­ing modal­ities are neg­a­tive. A ­large num­ber of anti­bod­ies ­against dif­fer­ent epi­topes of ­human neo­plas­tic ­breast tis­sue ­have ­been inves­ti­gat­ed pre­vi­ous­ly. However, a high­ly spe­cif­ic and sen­si­tive mono­clo­nal anti­body for immu­nos­cin­tig­ra­phy and radio­im­mu­no­ther­a­py has not yet ­been ­found. This ­review address­es tumor­-bi­o­log­i­cal con­sid­er­a­tions, radio­iso­topes and radio­lab­el­ing meth­ods, ­tumor tar­gets and dif­fer­ent mono­clo­nal anti­bod­ies ­used for immu­nos­cin­tig­ra­phy (­incl. ­SPECT amd PET) of ­breast can­cer.

inizio pagina